Annual report pursuant to Section 13 and 15(d)

Revenue - Potential Milestone Payments (Details)

v3.8.0.1
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements - USD ($)
$ in Millions
Dec. 31, 2017
Dec. 31, 2016
Research, Development & Regulatory Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments $ 2,509  
Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments   $ 2,025
AstraZeneca | Research, Development & Regulatory Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments 1,111  
AstraZeneca | Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments   960
Servier | Research, Development & Regulatory Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments 1,040  
Servier | Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments   942
Roche | Research, Development & Regulatory Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments 290  
Roche | Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments   123
Other | Research, Development & Regulatory Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments $ 68  
Other | Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Potential milestone payments   $ 0